Pancreatic Duodenal Homeobox Factor-1 (PDX-1) and Neurogenin-3 (NGN-3) in Gestational Diabetes

NCT03964987 | Completed

• 1 other identifier: 2016-09-481
• Study Type: observational
• Target: 48
• Locations: 1 country
• Sites: 1

Brief Summary

Introduction: Depletion of the ability of the cells ß to secrete the amount of insulin required by pregnancy, increasing the risk of develop Gestational Diabetes Mellitus (GDM). The aim was to contrast the messenger RNA (mRNA) expression of the pancreatic duodenal homeobox factor-1 (PDX-1) and Neurogenin-3 (Ngn-3) in peripheral blood of pregnant women with GDM versus women with normal pregnancies. Material and methods: This was a prospective, clinical and cross-sectional study, conforming two groups of pregnant women: a) patients with a healthy gestation and b) patients with GDM. Besides anthropometry and routine laboratorial test, real-time polymerase chain reaction (Real-Time PCR), was used to quantify the expression of PDX-1 and NGN-3.

Conditions

Gestational Diabetes

Keywords

PDX-1; NGN-3; Glucose

Outcome Measures

Primary Outcomes (1)

• ARNm expression

  Expression of the genes PDX-1 and NGN-3

  Nine months

Study Arms (2)

Control group

Women with normoevolutionary gestation.

Problem group

Patients with GDM.

Eligibility Criteria

• Age: 18 Years - 45 Years
• Gender Eligibility Details: Pregnant women
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)
• Sampling Method: Non-Probability Sample

Study Population

Pregnant women attended in the Maternal-Fetal Medicine Service of the HMPMP.

You may qualify if:

• Pregnant women older than 18 years old.

You may not qualify if:

• Those with autoimmune diseases, heart disease, nephropathy, liver disease or any other chronic condition.

Sponsors & Collaborators

• Materno-Perinatal Hospital of the State of Mexico: lead
• Universidad Autonoma del Estado de Mexico: collaborator

Study Sites (1)

Materno-Perinatal Hospital "Mónica Pretelini"

Toluca, 50130, Mexico

Location

Related Publications (4)

• Sandikci M, Karagenc L, Yildiz M. Changes on the Pancreas in Experimental Diabetes and the Effect of Lycopene on These Changes: Pdx-1, Ngn-3, and Nestin Expressions. Anat Rec (Hoboken). 2017 Dec;300(12):2200-2207. doi: 10.1002/ar.23687. Epub 2017 Sep 26.

  PMID: 28921917 BACKGROUND

• Gu G, Dubauskaite J, Melton DA. Direct evidence for the pancreatic lineage: NGN3+ cells are islet progenitors and are distinct from duct progenitors. Development. 2002 May;129(10):2447-57. doi: 10.1242/dev.129.10.2447.

  PMID: 11973276 BACKGROUND

• Wang L, Fan H, Zhou L, Wu Y, Lu H, Luo J. Altered expression of PGC-1alpha and PDX1 and their methylation status are associated with fetal glucose metabolism in gestational diabetes mellitus. Biochem Biophys Res Commun. 2018 Jun 18;501(1):300-306. doi: 10.1016/j.bbrc.2018.05.010. Epub 2018 May 7.

  PMID: 29730292 RESULT

• Plows JF, Stanley JL, Baker PN, Reynolds CM, Vickers MH. The Pathophysiology of Gestational Diabetes Mellitus. Int J Mol Sci. 2018 Oct 26;19(11):3342. doi: 10.3390/ijms19113342.

  PMID: 30373146 RESULT

MeSH Terms

Conditions

Diabetes, Gestational

Condition Hierarchy (Ancestors)

Pregnancy Complications; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Diabetes Mellitus; Glucose Metabolism Disorders; Metabolic Diseases; Nutritional and Metabolic Diseases; Endocrine System Diseases

Study Officials

• Hugo Mendieta Zerón, PhD.

  Maternal-Perinatal Hospital "Mónica Pretelini Sáenz"

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: CASE CROSSOVER
• Time Perspective: PROSPECTIVE
• Target Duration: 9 Months
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Chief of the Research Department

Study Record Dates

• First Submitted: May 21, 2019
• First Posted: May 28, 2019
• Study Start: January 1, 2018
• Primary Completion: August 30, 2018
• Study Completion: December 31, 2018
• Last Updated: May 28, 2019

Record last verified: 2019-05

Locations

ME (1)